Boston Scientific (BSX) vs. The Competition Financial Survey

Boston Scientific (NYSE:BSX) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its competitors? We will compare Boston Scientific to related companies based on the strength of its risk, institutional ownership, valuation, earnings, dividends, analyst recommendations and profitability.

Valuation & Earnings

This table compares Boston Scientific and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Boston Scientific	$20.07 billion	$2.90 billion	19.14
Boston Scientific Competitors	$1.88 billion	$136.81 million	12.57

Boston Scientific has higher revenue and earnings than its competitors. Boston Scientific is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Boston Scientific has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, Boston Scientific’s competitors have a beta of 2.57, suggesting that their average share price is 157% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Boston Scientific and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boston Scientific	2	8	20	1	2.65
Boston Scientific Competitors	4290	10574	18359	830	2.46

Boston Scientific presently has a consensus target price of $61.43, indicating a potential upside of 36.00%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 20.48%. Given Boston Scientific’s stronger consensus rating and higher possible upside, research analysts plainly believe Boston Scientific is more favorable than its competitors.

Profitability

This table compares Boston Scientific and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Boston Scientific	16.62%	18.61%	10.58%
Boston Scientific Competitors	-304.20%	-315.07%	-22.11%

Insider and Institutional Ownership

89.1% of Boston Scientific shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 0.3% of Boston Scientific shares are held by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Boston Scientific beats its competitors on 11 of the 13 factors compared.

Boston Scientific Company Profile

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.